Eli Lilly said Monday that some Medicare beneficiaries could pay more than the widely cited $50 monthly cap for weight‑loss drugs under a new federal coverage model, cautioning that cost‑sharing may vary across a limited number of basic Medicare Part D plans. The company said in a press release that most participating plans are expected to honor the $50 out‑of‑pocket limit, but a small subset may not fully comply with the cap.
The issue stems from a voluntary program launched by the Centers for Medicare and Medicaid Services that aims to expand coverage for GLP‑1 drugs used to treat obesity and diabetes. Under the model, CMS negotiates standardized coverage terms and net prices with drugmakers, with the goal of lowering patient costs while pairing drug coverage with lifestyle and behavioral support.
CMS previously said eligible Medicare beneficiaries would pay $50 per month for a supply of GLP‑1 medications, including Lilly’s injectable drugs Zepbound and Mounjaro. Lilly said Monday that while the majority of Medicare plan options will follow that pricing framework, beneficiaries enrolled in certain basic plans could see different cost‑sharing requirements.
The drugmaker said it plans to actively educate patients and physicians about plan options, including programs designed to smooth out‑of‑pocket costs over the course of the year. Lilly said those efforts are intended to help patients access its medications at the lowest possible cost within the existing Medicare structure.
Lilly also noted that its GLP‑1 treatments will become available through participating Medicare Part D plans beginning Jan. 1, 2027, marking a significant shift in how weight‑loss drugs are covered under the federal program. Medicare Part D is administered through private insurers and helps beneficiaries pay for outpatient prescription medications.
This is a breaking news story. Updates to follow.
Read the full article here
